Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Bacterial Curli Amyloid: Researchers Examine the Role of Bacterial Infection in Lupus Pathology

Richard Quinn  |  June 3, 2016

Flasks_gopixa_Shutterstock_500x270Although most research efforts focus on the genetic and environmental factors of systemic lupus erythematosus (SLE), novel new research highlights the effect bacterial infections can have on lupus activation and flares. The article, “Amyloid-DNA Composites of Bacterial Biofilms Stimulate Autoimmunity,” explains how researchers identified the amyloid protein curli, a component of bacterial biofilms, as a trigger for “immune activation and production of autoantibodies in lupus-prone and wild-type mice.”1

“Repeated administration of these curli-DNA actually accelerate the onset of lupus in lupus-prone mice,” says Stefania Gallucci, MD, associate professor and associate chair of the Microbiology and Immunology Department at the Lewis Katz School of Medicine of Temple University in Philadelphia. “For years and years, rheumatologists and immunologists have known there is a connection between infections and lupus. But we still don’t know much about the molecules involved and the mechanisms of infection that affect lupus. We have discovered one molecule—bacterial curli amyloid—that is one of the ways infection can trigger or make lupus [flares] worse.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Infections are known to be key factors in lupus patient mortality and hospitalization. Better knowledge of biofilms and how they activate the immune system might lead to changes in lupus treatments. And study data suggest clinicians keep an eye out for lupus patients who present with chronic infections, such as urinary tract infections.

The Research Team: Dr. Stefania Gallucci (center) with colleagues Cagla Tukel, MD, (left), a microbiologist and expert in bacterial amyloids, and Roberto Caricchio, MD, a rheumatologist and director of the Lupus Clinic at Temple University School of Medicine in Philadelphia.

The Research Team: Dr. Stefania Gallucci (center) with colleagues Cagla Tukel, MD, (left), a microbiologist and expert in bacterial amyloids, and Roberto Caricchio, MD, a rheumatologist and director of the Lupus Clinic at Temple University School of Medicine in Philadelphia.

“The key thing for practicing rheumatologists,” Dr. Gallucci says, “is to pay attention to infections in lupus patients, not only as an effect of the immunosuppression, but actually as a cause of activation and flare in lupus. Treating the infection can be beneficial for long-term lupus disease.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Gallucci notes the contributions to the research of her collaborators, microbiologist Cagla Tukel, PhD, and Roberto Caricchio, MD, of Temple’s Division of Rheumatology. The next step for the team, she says, is to take the work into Dr. Caricchio’s lupus clinic in translational studies.

“This is just the beginning of a new line of research that we want to pursue,” she says.


Richard Quinn is a freelance writer in New Jersey.

Reference

  1. Gallo PM, Rapsinski GJ, Wilson RP, et al. Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity. 2015 Jun 16;42(6):1171-84. doi: 10.1016/j.immuni.2015.06.002.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:bacteriaInfectionLupuspathologysystemic lupus erythematosus (SLE)

Related Articles

    The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease

    October 16, 2017

    An Unforgettable Story Her name was unforgettable. Not only did we share our given names—Simon and Simone, but her French-Canadian surname was based on this appellation, too. I was the junior resident working on our hospital’s nephrology service when she was admitted for evaluation of progressively worsening kidney disease and an overall failure to thrive….

    Early Fall 2022’s Awards, Appointments & Announcements in Rheumatology

    September 6, 2022

    Roberto Caricchio, MD, Now Chief of Rheumatology at UMass Chan Medical School As of July 1, Roberto Caricchio, MD, began a new appointment as chief of the Division of Rheumatology at UMass Chan Medical School, Worcester. He was formerly chief of the Section of Rheumatology at Lewis Katz School of Medicine at Temple University, Philadelphia,…

    A 52-Year-Old Lupus Paper Remains Important Today

    December 14, 2020

    Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythema­tosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…

    Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm

    November 14, 2020

    Roberto Caricchio, MD, discusses what trials of repurposed rheumatology drugs to treat COVID-19 cytokine storm have shown so far.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences